Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: Interim results from a phase 3, randomised, double-blind, placebo-controlled trial Academic Article uri icon

Overview

MeSH Major

  • Infant, Very Low Birth Weight
  • Leukemoid Reaction

abstract

  • Gilead Sciences Inc.

publication date

  • January 2017

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1016/S1470-2045(16)30671-4

Additional Document Info